April 1, 2008 - Despite the known increased rates of mortality and restenosis for diabetics versus non-diabetics in patients with cardiovascular disease, the TAXUS Stent had comparable levels of late loss and target lesion revascularization (TLR) across these patient populations, according to results from TAXUS IV and TAXUS V randomized clinical trials.
The analysis compared the safety and efficacy of the TAXUS Express Paclitaxel-Eluting Coronary Stent System in diabetic versus non-diabetic patients.
